Alzamend Neuro Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Year	2023	2022	2021	2020	2019
Net Income	-14.88	-12.36	-5.05	-4.41	-4.86
Depreciation & Amortization	0.02	0	0	0	0
Share-Based Compensation	3.58	4.41	2.03	1.8	0.4
Other Operating Activities	2.35	1.34	0.3	0.26	3.42
Operating Cash Flow	-8.92	-6.61	-2.71	-2.35	-1.05
Capital Expenditures	0	-0.11	0	0	0
Acquisitions	0	0	0.1	0.11	0.23
Investing Cash Flow	0	-0.11	0.1	0.11	0.23
Share Issuance / Repurchase	0	18.91	2.2	2.31	0.24
Debt Issued / Paid	0	-0.06	2.25	-0.02	0.07
Financing Cash Flow	0	18.85	4.45	2.29	0.31
Net Cash Flow	-8.92	12.13	1.84	0.05	-0.5
Free Cash Flow	-8.92	-6.72	-2.71	-2.35	-1.05
Free Cash Flow Per Share	-1.37	-1.13	-0.56	-0.49	-0.27

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).